Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07680868 · ClinicalTrials.gov registry record
Caris Chromoseq Data Collection
A clinical trial, sponsored by Caris Science.
- Recruiting
- Registry status
- 300
- Enrollment target
NCT07680868: Recruiting study, sponsored by Caris Science.
NCT07680868 is a clinical trial that is actively recruiting participants, run by Caris Science. The registered enrollment target is 300 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07680868 is actively recruiting participants, sponsored by Caris Science.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
Study Summary
The study will collect clinical data on patients who receive the Caris Chromoseq assay for an underlying hematologic malignancy. The assay provides risk stratification for patients with acute myeloid leukemia (AML) myelodysplastic syndrome (MDS), or myeloproliferative neoplasms (MPN). The hypothesis of the study is that Caris Chromoseq compares favorably to conventional cytogenetics, FISH, and NGS analysis in terms of risk stratification capabilities, ease of use, and turnaround time.
Primary Outcome
To describe the concordance between the Caris Chromoseq assay and conventional cytogenetics performed in risk stratification of AML, MDS, and MPN
Interventions
- DIAGNOSTIC_TEST Caris Chromoseq
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-07 |
| Est. Completion | 2029-07 |
What NCT07680868 shows while recruiting
NCT07680868 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Caris Chromoseq is the first listed.
NCT07680868 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07680868 about?
NCT07680868 is a clinical study titled "Caris Chromoseq Data Collection". The study will collect clinical data on patients who receive the Caris Chromoseq assay for an underlying hematologic malignancy. The assay provides risk stratification for patients with acute myeloid leukemia (AML) myelodysplastic syndrome (MDS), or myeloproliferative neoplasms (MPN). The hypothesis...
What is the current status of trial NCT07680868?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2026-07. Estimated completion is 2029-07.
What interventions are being tested in trial NCT07680868?
The interventions under investigation include: Caris Chromoseq (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07680868?
This trial is sponsored by Caris Science, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia